Article
Radiology, Nuclear Medicine & Medical Imaging
Yixing Yu, Yanfen Fan, Ximing Wang, Mo Zhu, Mengjie Hu, Cen Shi, Chunhong Hu
Summary: The study developed a Gd-EOB-DTPA-enhanced MRI radiomics model for preoperative prediction of VETC and patient prognosis in hepatocellular cancer (HCC). The peritumoral radiomics model showed higher AUC than intratumoral model and was an independent predictor of early recurrence and progression-free survival (PFS). The radiomics models may be useful in preoperatively predicting VETC and patient prognosis.
EUROPEAN RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Jie Cheng, Xiaofeng Li, Limei Wang, Fengxi Chen, Yiman Li, Guojiao Zuo, Mi Pei, Huarong Zhang, Linze Yu, Chen Liu, Jian Wang, Qi Han, Ping Cai, Xiaoming Li
Summary: This study compared the performance of Gd-EOB-DTPA MRI and CT in differentiating MTM-HCC from non-MTM-HCC. The results showed that Gd-EOB-DTPA MRI outperformed CT in both the training and external validation cohorts. A nomogram incorporating AFP, PT-INR, and MRI features demonstrated high diagnostic performance for MTM-HCC in the external validation cohort. Intratumor necrosis or ischemia was found to be an independent indicator for poor prognosis.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Oncology
Ziwei Liu, Shaomin Yang, Xinjie Chen, Chun Luo, Jieying Feng, Haixiong Chen, Fusheng Ouyang, Rong Zhang, Xiaohong Li, Wei Liu, Baoliang Guo, Qiugen Hu
Summary: T1rt-Pre and T1rt-20min showed strong positive correlation with Ki-67 expression in HCC, and the nomogram based on Gd-EOB-DTPA enhanced MRI combined with T1 mapping effectively predicted high Ki-67 expression in HCC with good concordance indices in the training and validation cohorts.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Yanfen Fan, Yixing Yu, Ximing Wang, Mengjie Hu, Mingzhan Du, Lingchuan Guo, Shifang Sun, Chunhong Hu
Summary: This study utilized texture analysis based on GdEOB-DTPA-enhanced MRI to identify VETC-positive HCC, finding specific texture features that were significantly associated with VETC-positive HCC and could effectively differentiate this type of tumor.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Gastroenterology & Hepatology
Han-Dan Zhang, Xiao-Ming Li, Yu-Han Zhang, Fang Hu, Liang Tan, Fang Wang, Yang Jing, Da-Jing Guo, Yang Xu, Xian-Ling Hu, Chen Liu, Jian Wang
Summary: This study established and compared the efficacy of the clinicoradiological model, radiomics model, and clinicoradiological-radiomics hybrid model in predicting the microvascular invasion of hepatocellular carcinoma using Gd-EOB-DTPA enhanced MRI. The results showed that the hybrid model provided the best prediction results.
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY
(2023)
Article
Oncology
Wolf Baeumler, Philipp Wiggermann, Lukas Luerken, Marco Dollinger, Christian Stroszczynski, Lukas P. Beyer, Andreas Schicho
Summary: The study investigated local tumor progression after IRE treatment of HCC and found MR imaging features helpful in identifying re-grown viable tumors. LTP was mainly detected in the peripheral ablation zone, with T2 BLADE and diffusion sequences aiding detection in the peripheral zone, while T1 p.v. and T1 d.p. showed the highest sensitivity in the central zone.
Article
Oncology
Chengming Qu, Qiang Wang, Changfeng Li, Qiao Xie, Ping Cai, Xiaochu Yan, Ernesto Sparrelid, Leida Zhang, Kuansheng Ma, Torkel B. Brismar
Summary: The aim of this study is to establish and validate a radiomics-based model using preoperative Gd-EOB-DTPA-enhanced MRI to predict microvascular invasion (MVI) in patients with hepatocellular carcinoma <= 5 cm.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Hiroshige Mori, Hanaka Machimura, Amika Iwaya, Masaru Baba, Ken Furuya
Summary: The study confirmed the convertibility from liver-spleen contrast (LSC) into receptor index (LHL15) and demonstrated that the estimated LHL15 (eLHL15) from LSC can replace LSC as an index to evaluate liver function, with a certain feasibility and accuracy.
SCIENTIFIC REPORTS
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhaoqi Shi, Wenli Cai, Xu Feng, Jingwei Cai, Yuelong Liang, Junjie Xu, Junhao Zhen, Xiao Liang
Summary: This study aimed to evaluate the effectiveness of radiomics analysis based on Gd-EOB-DTPA enhanced hepatic MRI for functional liver reserve assessment in HCC patients. The results showed that radiomics analysis can be used to assess functional liver reserve and effectively identify patients with ICG R15<10%.
ACADEMIC RADIOLOGY
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhe Huang, PingPing Zhou, ShanShan Li, Kaiyan Li
Summary: This study showed that dynamic contrast-enhanced ultrasonography (DCE-US) parameters are related to Ki-67 expression in patients with hepatocellular carcinoma (HCC). There were significant differences in clinicopathological features between the high and low Ki-67 expression groups. Certain parameters in the arterial phase and Kupffer phase were significantly different between HCC lesions and distal liver parenchyma, and these differences may contribute to a more accurate diagnosis of the high Ki-67 expression group.
INSIGHTS INTO IMAGING
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Yanfen Fan, Yixing Yu, Ximing Wang, Mengjie Hu, Chunhong Hu
Summary: This study investigated the use of radiomics models derived from enhanced MRI images to predict Ki-67 expression in hepatocellular carcinoma. The arterial phase radiomics model showed better predictive performance, with the combined model including AP Rad-score and serum AFP levels improving the predictive accuracy further. The findings suggest that a combined model based on enhanced MRI can accurately predict Ki-67 expression in HCC preoperatively.
BMC MEDICAL IMAGING
(2021)
Review
Oncology
Ying Wu, Meilin Zhu, Yiming Liu, Xinyue Cao, Guojin Zhang, Longlin Yin
Summary: This study investigated the association between microvascular invasion (MVI) and the peritumoral imaging features of gadolinium ethoxybenzyl DTPA-enhanced magnetic resonance imaging (Gd-EOB-DTPA-enhanced MRI) in hepatocellular carcinoma (HCC). The results showed that the peritumoral imaging features had high specificity but low sensitivity in predicting hepatic MVI, indicating that it can be used as a noninvasive, excluded diagnosis.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Li-Li Wang, Jun-Feng Li, Jun-Qiang Lei, Shun-Lin Guo, Jin-Kui Li, Yong-Sheng Xu, Yu Dou
Summary: The study found that preoperative Gd-EOB-DTPA dynamic enhanced MRI is a potential noninvasive diagnostic marker for MVI and pathological grade of HCC, with higher SIAp/Al potentially indicating poor prognosis after surgery.
Article
Radiology, Nuclear Medicine & Medical Imaging
Ningbin Luo, Xiangyang Huang, Yinan Ji, Guanqiao Jin, Yunying Qin, Bangde Xiang, Danke Su, Weizhong Tang
Summary: This study found that the functional liver imaging score (FLIS) based on preoperative gadoxetic acid-enhanced MRI can predict posthepatectomy liver failure (PHLF) in hepatocellular carcinoma (HCC) patients. FLIS has a higher predictive power than the MELD score, ALBI score, and ICG-R15 clearance.
EUROPEAN RADIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Rencheng Zheng, Chunzi Shi, Chengyan Wang, Nannan Shi, Tian Qiu, Weibo Chen, Yuxin Shi, He Wang
Summary: The study aimed to automatically stage liver fibrosis in patients with hepatitis B using a dynamic radiomics model, which achieved remarkable performance in distinguishing significant fibrosis, advanced fibrosis, and cirrhosis in the test set. Time-domain features were found to play an important role in the classification models, making the dynamic radiomics model highly accurate for automatic hepatic fibrosis staging.
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura
Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.
HEPATOLOGY RESEARCH
(2023)
Article
Gastroenterology & Hepatology
Dominique Thabut, Masatoshi Kudo
Summary: Portal hypertension and hepatocellular carcinoma commonly coexist and their association affects the prognosis of cirrhosis patients. The interplay between these conditions has therapeutic significance in terms of treating HCC and managing PHT complications. The management recommendations for PHT have been revised, with new screening and prophylaxis indications. PHT may limit locoregional therapies and TIPS placement can be considered for HCC patients. New systemic HCC therapies can impact PHT levels and increase the risk of bleeding. Prevention and adequate treatment of PHT complications are important, particularly in advanced HCC cases. This expert opinion discusses specific aspects of managing both conditions, incorporating recent data in the HCC field.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Mara Persano, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Jose Presa Ramos, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Bernardo Stefanini, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Margarida Montes, Caterina Vivaldi, Caterina Solda, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Summary: This real-world study investigates the association between the prognostic nutritional index (PNI) and clinical outcomes in HCC patients treated with atezolizumab plus bevacizumab. The study shows that high PNI is associated with longer overall survival and progression-free survival.
Editorial Material
Oncology
Masatoshi Kudo
Article
Oncology
Masatoshi Kudo, Richard S. Finn, Ann-Lii Cheng, Andrew X. Zhu, Michel Ducreux, Peter R. Galle, Naoya Sakamoto, Naoya Kato, Michitaka Nakano, Jing Jia, Arndt Vogel
Summary: This exploratory analysis examined the prognostic impact of baseline albumin-bilirubin (ALBI) score in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab + bevacizumab or sorafenib. The study found that atezolizumab + bevacizumab improved overall survival and progression-free survival compared to sorafenib in patients with ALBI score of 1, but not in patients with ALBI score of 2. ALBI grade appeared to be prognostic for outcomes in both treatment groups.
Article
Oncology
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stephane Cattan, Yee Chao, Abby B. Siegel, Ivan Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn
Summary: With extended follow-up, pembrolizumab demonstrated continued improvement in overall survival (OS) and progression-free survival (PFS) compared to placebo in advanced hepatocellular carcinoma (HCC) patients previously treated with sorafenib. The adverse event profile of pembrolizumab remained consistent with placebo.
Article
Oncology
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, Kaoru Tsuchiya, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Naoshi Nishida, Chikara Ogawa, Tetsu Tomonari, Noriaki Nakamura, Hidekatsu Kuroda, Atsushi Takebe, Yoshifumi Takeyama, Masaaki Hidaka, Susumu Eguchi, Stephen L. Chan, Masayuki Kurosaki, Namiki Izumi
Summary: The concept of curative conversion by combining systemic therapy and locoregional therapy in intermediate-stage HCC has not been reported before. This study aimed to show the value of curative conversion in immunotherapy-treated HCC. The results showed that 35% of patients achieved CR through resection, ablation, or super selective TACE.
Review
Oncology
Satoru Hagiwara, Naoshi Nishida, Masatoshi Kudo
Summary: Immunotherapy for hepatocellular carcinoma (HCC) is rapidly advancing, with a focus on analyzing the tumor immune environment and developing custom-made treatments. Understanding the immune environment of HCC is vital for selecting appropriate immune checkpoint inhibitors (ICIs) and managing their side effects. This summary aims to review the progress of immunotherapy in HCC and its implications for future treatment.
Article
Oncology
Naoshi Nishida, Tomoko Aoki, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Hiroshi Ida, Satoru Hagiwara, Yasunori Minami, Kazuomi Ueshima, Masatoshi Kudo
Summary: Cholangiocarcinoma (CCA) is a resistant cancer, and a majority of CCAs have a non-inflamed tumor phenotype resistant to treatment, including immune checkpoint inhibitors (ICIs). This study aimed to understand the molecular characteristics of non-inflamed CCAs. The genetic/epigenetic status of 36 CCAs was analyzed, and it was found that tumors with alterations in FGFR2 and IDH1/2 had a non-inflamed phenotype. Downregulation of genes involved in antigen presentation and DNA methylation were associated with the non-inflamed phenotype. These findings provide important insights for developing new strategies to treat CCA.
Review
Medicine, General & Internal
Yasuo Otsuka, Ken Kamata, Masatoshi Kudo
Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.
Article
Medicine, General & Internal
Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki
Summary: This study validated the assessment of sarcopenia using psoas muscle volume as a measure and found that sarcopenia was associated with shorter survival in patients with liver disease. The psoas muscle volume index (PMVI) may be useful in evaluating sarcopenia, including cases where sarcopenia cannot be diagnosed using the commonly used psoas muscle index (PMI).
Article
Biochemistry & Molecular Biology
Tomohiro Watanabe, Kosuke Minaga, Hajime Honjo, Masatoshi Kudo
Summary: The liver showed hypo-responsiveness to antigens and high doses of orally-administered ovalbumin (OVA) generated unique CD4+ T cells and tolerogenic dendritic cells that can suppress Th1 responses. OVA administration at high doses inhibited hepatitis development in mice with OVA-specific CD4+ T cells, and this was associated with downregulation of Th1 responses. The results suggest that high-dose oral antigen administration can suppress Th1-mediated hepatitis in an antigen-non-specific manner.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Review
Oncology
Yasunori Minami, Tomoko Aoki, Satoru Hagiwara, Masatoshi Kudo
Summary: Thermal ablation therapy, including RFA and MWA, is a widely used treatment for hepatocellular carcinomas. It achieves good outcomes with minimal invasiveness. Successful thermal ablation therapy requires understanding the principles and characteristics of the treatment, assessing the benefits and risks, precise needle control and visualization, utilizing imaging guidance techniques, and evaluating therapeutic response. This overview provides essential information for the clinical application of thermal ablation.
Article
Oncology
Masatoshi Kudo
